Drugs / HDIL-2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01266603 | Feb 2011 → Nov 2018 | melanoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HDIL-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01266603 ↗ |
| Route | Intravenous | “720,000 IU/kg by vein” NCT01266603 ↗ |